



Actinogen Medical

ASX ANNOUNCEMENT

CHANGE OF SHARE REGISTER NOTIFICATION

Sydney, 20 May 2016: Actinogen Medical Limited (ASX: ACW) advises the it will transfer responsibility for the maintenance of its Share Register to Link Market Services Limited (Link), effective from start of business on Monday, 23 May 2016.

The new Shares Registry details are as follows:

Link Market Services Limited

Street Address:

Level 12,
680 George Street,
SYDNEY NSW 2000

Postal Address:


Locked Bag A14
SYDNEY SOUTH NSW 1235

Australian Telephone: 1300 554 474
International Telephone: +61 1300 554 474
Facsimile: 02 9287 0303
Website: www.linkmarketservices.com.au

Lodgement of documentation by member organisations, security holders, and other interested parties must be made at the new address from Monday, 23 May 2016.

ENDS

Actinogen Medical

Dr Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multi-billion dollar market potential. The cost of Alzheimer's treatment in the US alone was estimated to be US\$250bn in 2013, with this cost estimated to increase to US\$1 trillion by 2050, outstripping the cost of treating all other diseases. Alzheimer's disease is now the second leading cause of death in Australia behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from existing Alzheimer's treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.

About Actinogen Medical

Actinogen Medical is focused on the treatment of Alzheimer's disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer's disease. The Company plans to undertake a Phase II study in mild Alzheimer's patients in 2016.